Abstract
Sporadic Creutzfeldt-Jakob disease (sCJD) presents as a rapidly progressive dementia which is usually fatal within six months. No clinical blood tests are currently available for diagnosis or disease monitoring. Here, we profiled blood microRNA (miRNA) expression in sCJD. Small RNA-sequencing of 57 sCJD patients and 48 healthy controls revealed differential expression of hsa-let-7i-5p, hsa-miR-16-5p, hsa-miR-93-5p and hsa-miR-106b-3p. Downregulation of hsa-let-7i-5p, hsa-miR-16-5p and hsa-miR-93-5p replicated in an independent cohort using quantitative PCR, with concomitant upregulation of four of their mRNA targets. Absence of correlation in cross-sectional analysis with clinical phenotypes paralleled the lack of association between rate of decline in miRNA expression and rate of disease progression in a longitudinal cohort of 50 samples from 21 sCJD patients. Finally, the miRNA signature showed a high level of accuracy in discriminating sCJD from Alzheimer’s disease (AD). These findings highlight novel molecular alterations in the periphery in sCJD which can provide information about differential diagnosis and improve mechanistic understanding of human prion diseases.
Competing Interest Statement
Prof. Collinge is a director and shareholder of D-Gen Limited (London), an academic spinout company working in the field of prion disease diagnosis, decontamination, and therapeutics. Prof. Schott has received research funding and PET tracer from AVID Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly); has consulted for Roche, Eli Lilly, Biogen and Merck, GE; received royalties from Oxford University Press and Henry Stewart Talks; given education lectures sponsored by Eli Lilly, Biogen and GE; and serves on a Data Safety Monitoring Committee for Axon Neuroscience SE. No other disclosures were reported.
Funding Statement
This study was funded by the UK Medical Research Council and the National Institute of Health Research (NIHR) Biomedical Research Centre at UCL Hospitals NHS Foundation Trust. SM and JC are NIHR Senior Investigators. JMS is supported by the NIHR University College London Hospitals Biomedical Research Centre, Wolfson Foundation, Engineering and Physical Sciences Research Council, MRC Dementias Platform UK, Alzheimers Research UK (ARUK), Brain Research UK, Weston Brain Institute and European Union Horizon 2020 research and innovation programme. RWP is funded by an NIHR clinical lectureship, AGBT was funded by clinical lectureships from NIHR and ARUK, LCD was supported by a Leonard Wolfson Foundation PhD fellowship, AN is a MRC Clinical Research Training Fellow, FG is funded by a grant from the National Institute for Health Research, and THM is funded by a clinical research fellowship from the Alzheimers Society.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The sequencing data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus (Edgar et al., 2002) and are accessible through GEO Series accession number GSE140069.
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE140069
